Correspondence

Cost considerations in determining the affordability of adjuvant trastuzumab in breast cancer

Bookmark and Share
M Sereda, R P Abratt

Authors' affiliations

M Sereda, Head: Medical Affairs Management Centre South Africa, Roche Products (Pty) Ltd Medical Department, Sandton, South Africa

R P Abratt, Head of Clinical Governance, Independent Clinical Oncology Network; Emeritus Professor of Radiation Oncology, University of Cape Town, South Africa

Full Text

PDF (154KB)

Cite this article

South African Medical Journal 2017;107(1):8-9. DOI:10.7196/SAMJ.2017.v107i1.12152

Article History

Date submitted: 2016-12-21
Date published: 2016-12-21

Article Views

Abstract views: 734
Full text views: 1651

Comments on this article

*Read our policy for posting comments here